東方精工(002611.SZ):擬以5000萬元參投合夥企業 以投向軍工、航空航天領域標的等
格隆匯3月31日丨東方精工(002611.SZ)公佈,公司全資子公司海南省億能投資有限公司(“億能投資”),近日與深圳市尚道眾盈投資基金管理有限公司(“尚道投資”或“普通合夥人”)以及其他25名合夥企業有限合夥人,簽署了《嘉興尚道國豐股權投資合夥企業(有限合夥)合夥協議》,共同投資嘉興尚道國豐股權投資合夥企業(有限合夥)(“基金”或“合夥企業”)。億能投資以自有資金認繳出資5000萬元人民幣,出資比例20.83%,為合夥企業之有限合夥人之一。
投資方向:(1)軍工、航空航天領域標的;(2)銀行存款、銀行理財產品、央行票據、國債、貨幣市場基金等貨幣市場工具。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.